"Drug Labeling" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Use of written, printed, or graphic materials upon or accompanying a drug container or wrapper. It includes contents, indications, effects, dosages, routes, methods, frequency and duration of administration, warnings, hazards, contraindications, side effects, precautions, and other relevant information.
| Descriptor ID |
D004348
|
| MeSH Number(s) |
E05.916.310 J01.576.655.750.321.400 J01.576.761.300.400
|
| Concept/Terms |
Drug Labeling- Drug Labeling
- Labeling, Drug
- Drug Labelling
- Labelling, Drug
- Package Inserts, Drug
- Drug Package Insert
- Drug Package Inserts
- Insert, Drug Package
- Inserts, Drug Package
- Package Insert, Drug
- Product Labeling, Drug
- Drug Product Labeling
- Labeling, Drug Product
Black Box Warning- Black Box Warning
- Black Box Warnings
- Box Warning, Black
- Box Warnings, Black
- Warning, Black Box
- Warnings, Black Box
- Boxed Warning
- Boxed Warnings
- Warning, Boxed
- Warnings, Boxed
|
Below are MeSH descriptors whose meaning is more general than "Drug Labeling".
Below are MeSH descriptors whose meaning is more specific than "Drug Labeling".
This graph shows the total number of publications written about "Drug Labeling" by people in this website by year, and whether "Drug Labeling" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2012 | 0 | 1 | 1 |
| 2016 | 2 | 0 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Labeling" by people in Profiles.
-
Ablefoni K, Buchholz A, Ueberham L, Hilbert S, Dagres N, Husser D, Hindricks G, Bollmann A. Initial rivaroxaban dosing in patients with atrial fibrillation. Clin Cardiol. 2019 Oct; 42(10):873-880.
-
Buchholz A, Ueberham L, Gorczynska K, Dinov B, Hilbert S, Dagres N, Husser D, Hindricks G, Bollmann A. Initial apixaban dosing in patients with atrial fibrillation. Clin Cardiol. 2018 May; 41(5):671-676.
-
Pokorney SD, Shrader P, Thomas L, Fonarow GC, Kowey PR, Singer DE, Ansell J, Gersh BJ, Mahaffey KW, Hylek EM, Go AS, Piccini JP, Peterson ED. Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. Circulation. 2016 10 11; 134(15):1122-1124.
-
Pirlamarla P, Bond RM. FDA labeling of NSAIDs: Review of nonsteroidal anti-inflammatory drugs in cardiovascular disease. Trends Cardiovasc Med. 2016 11; 26(8):675-680.
-
Selbst SM, Osterhoudt K. Pediatric emergency medicine: legal briefs. Pediatr Emerg Care. 2012 Dec; 28(12):1402-5.
-
Lester P, Kohen I, Stefanacci RG, Feuerman M. Antipsychotic drug use since the FDA black box warning: survey of nursing home policies. J Am Med Dir Assoc. 2011 Oct; 12(8):573-7.
-
Ong KL, Villarraga ML, Lau E, Carreon LY, Kurtz SM, Glassman SD. Off-label use of bone morphogenetic proteins in the United States using administrative data. Spine (Phila Pa 1976). 2010 Sep 01; 35(19):1794-800.
-
Budnitz DS, Lewis LL, Shehab N, Birnkrant D. CDC and FDA response to risk of confusion in dosing Tamiflu oral suspension. N Engl J Med. 2009 Nov 05; 361(19):1913-4.
-
Statler JD, Towbin RB, Ronsivalle JA, Oteham A, Miller DL, Grassi CJ, Brown DB, D'Agostino HR, Khan AA, Kundu S, Roberts AC, Saiter CK, Schwartzberg MS, Vedantham S, Wallace MJ, Cardella JF. Recommendations for the implementation of Joint Commission guidelines for labeling medications. J Vasc Interv Radiol. 2008 Nov; 19(11):1531-5.
-
Pinninti NR, Mago R. Injection site pain with long-acting risperidone. J Clin Psychiatry. 2005 May; 66(5):656-7; author reply, 657.